Forest Laboratories, Inc. FRX today announced it will be presenting
data on cariprazine at the American College of Neuropsychopharmacology Annual
Meeting scheduled December 2-6, 2012 in Hollywood, FL. Forest Laboratories,
Inc recently submitted a New Drug Application to the U.S. Food and Drug
Administration (FDA) for cariprazine for the treatment of schizophrenia and
the acute treatment of manic or mixed episodes associated with Bipolar I
disorder.
The cariprazine results will be announced in 3 poster presentations:
* Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia:
A Phase III, International, Randomized, Double-blind, Placebo-controlled
Trial (Poster 9: Wednesday, December 5 from 5:30 pm - 7:30 pm EST)
* Cariprazine Exhibits Dopamine D[3] Receptor-Dependent Antidepressant-Like
Activity in the Chronic Unpredictable Stress Model of Anhedonia (Poster
12: Monday, December 3 from 5:30 pm - 7:30 pm EST)
* Effects of Chronic Cariprazine Administration on Serotonin and Glutamate
Receptor Subtypes (Poster 161: Monday, December 3 from 5:30 pm - 7:30 pm
EST)
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in